Radient Pharmaceuticals (RPC) Reports Q1 Loss of $0.13, Revenue Falls Y/Y
Radient Pharmaceuticals (NYSE: RPC) reported Q1 EPS of ($0.13), versus ($0.10) reported last year. Revenue for the quarter came in at $30.66 million, versus $36.85 million reported last year.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Synopsys, Inc. (SNPS) Misses Q2 EPS by 2c; Issues Confident Q3 Outlook; Guides FY12
- Taro Pharmaceutical Industries (TARO) Nearly Doubles Q1 EPS to 1.06
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
